Potassium salt preparations (≥100 mg per tablet) must include a warning about which risk?

Potassium salt preparations (≥100 mg per tablet) must include a warning about which risk?

• A. Allergy risk
• B. No warning
• C. Small-bowel lesions risk
• D. Potassium toxicity risk

Answer: (C)

High-dose potassium salt tablets can irritate the lining of the gastrointestinal tract, and there have been documented cases of injury to the small intestine from these solid forms. Because a tablet delivering 100 mg or more of elemental potassium can create a concentrated local exposure as it travels through the GI tract, labeling requires a warning about the risk of small-bowel lesions, including ulcers or related complications. This safety warning helps clinicians and patients monitor for GI symptoms and consider alternative forms or dosing if there’s any existing GI disease or risk. While hyperkalemia is a general concern with potassium supplements, the specific warning in this context is about the potential for small-bowel mucosal injury.

High-dose potassium salt tablets can irritate the lining of the gastrointestinal tract, and there have been documented cases of injury to the small intestine from these solid forms. Because a tablet delivering 100 mg or more of elemental potassium can create a concentrated local exposure as it travels through the GI tract, labeling requires a warning about the risk of small-bowel lesions, including ulcers or related complications. This safety warning helps clinicians and patients monitor for GI symptoms and consider alternative forms or dosing if there’s any existing GI disease or risk. While hyperkalemia is a general concern with potassium supplements, the specific warning in this context is about the potential for small-bowel mucosal injury.